| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
The primary targets of methyltetrazine-amine hydrochloride are not biological targets but rather chemical reaction partners in bioorthogonal labeling applications. The methyltetrazine group specifically reacts with strained alkynes (e.g., trans-cyclooctene, bicyclononyne) via IEDDA cycloaddition. This reaction is highly selective and rapid, making it suitable for labeling biomolecules in complex biological environments. The amine group provides a handle for conjugation to proteins, antibodies, or other biomolecules via amide bond formation.
|
|---|---|
| ln Vitro |
In vitro activity of methyltetrazine-amine hydrochloride refers to its chemical reactivity in bioorthogonal labeling reactions. The compound demonstrates rapid and selective reaction with strained alkynes via IEDDA cycloaddition. The reaction kinetics are among the fastest for bioorthogonal reactions, with second-order rate constants typically in the range of 10-100 M-1s-1. The compound can be used to label biomolecules that have been functionalized with strained alkynes, enabling detection or purification of the labeled species.
|
| ln Vivo |
In vivo activity data for methyltetrazine-amine hydrochloride are related to its use in bioorthogonal labeling in living systems. The compound can be used for pretargeted imaging or therapy applications where a tetrazine-modified biomolecule is administered followed by a radiolabeled or drug-loaded trans-cyclooctene probe. The rapid and selective reaction enables specific labeling of target tissues or cells in vivo. These applications have been demonstrated in preclinical imaging and therapeutic studies.
|
| Enzyme Assay |
Non-cellular assays for methyltetrazine-amine hydrochloride typically involve characterizing its reactivity in IEDDA cycloaddition reactions. The reaction kinetics with various strained alkynes are measured using UV-Vis spectroscopy or HPLC. The compound's stability in biological media is assessed by incubating it in serum or buffer and monitoring degradation over time. These cell-free systems allow for precise characterization of the compound's chemical properties and reactivity.
|
| Cell Assay |
Cellular assays for methyltetrazine-amine hydrochloride are conducted in cell culture to evaluate its bioorthogonal labeling efficiency. Cells expressing or modified with strained alkyne-functionalized biomolecules are treated with the tetrazine compound, and labeling efficiency is assessed by fluorescence microscopy or flow cytometry if the compound is fluorescently labeled. Cytotoxicity of the compound is evaluated using standard cell viability assays to ensure compatibility with live-cell experiments.
|
| Animal Protocol |
In vivo animal experiments for methyltetrazine-amine hydrochloride typically involve pretargeted imaging or therapy studies. The compound (or a conjugate) is administered to mice bearing tumors or other targets that express strained alkyne-functionalized biomolecules. This is followed by administration of a radiolabeled or drug-loaded trans-cyclooctene probe. Imaging or biodistribution studies are performed to assess target-specific accumulation. Toxicity and pharmacokinetics are also evaluated in these studies.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of methyltetrazine-amine hydrochloride depend on its formulation and administration route. As a small molecule, it may be rapidly cleared from circulation. For in vivo pretargeting applications, the compound is typically administered intravenously, and its clearance kinetics are optimized to achieve a favorable target-to-background ratio. The compound's stability in blood and its distribution to tissues are important factors for successful in vivo labeling.
|
| Toxicity/Toxicokinetics |
Dosing and toxicity studies of methyltetrazine-amine hydrochloride in animal models have shown that the compound is generally well-tolerated at the doses used for imaging applications. The compound is not intended for therapeutic use at high doses. Standard laboratory safety precautions should be followed when handling the compound. Its safety profile is favorable for research applications, with no significant toxicity reported at typical labeling concentrations.
|
| References |
[1]. Antoine Maruani, et al. A Plug-and-Play Approach for the De Novo Generation of Dually Functionalized Bispecifics. Bioconjug Chem. 2020 Mar 18;31(3):520-529.
|
| Additional Infomation |
Methyltetrazine-amine hydrochloride is a research tool used in bioorthogonal chemistry for labeling and imaging applications. The IEDDA reaction between tetrazines and strained alkynes is one of the fastest bioorthogonal reactions, enabling efficient labeling in complex biological systems. The amine hydrochloride salt provides good water solubility and a functional handle for conjugation. The compound is widely used in chemical biology, molecular imaging, and drug delivery research.
|
| Molecular Formula |
C10H12CLN5
|
|---|---|
| Molecular Weight |
237.688779830933
|
| Exact Mass |
237.078
|
| CAS # |
1596117-29-1
|
| Related CAS # |
Methyltetrazine-Amine;1345955-28-3
|
| PubChem CID |
118239091
|
| Appearance |
Pale purple to purple solid powder
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
16
|
| Complexity |
182
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC1=NN=C(N=N1)C2=CC=C(C=C2)CN.Cl
|
| InChi Key |
NIGOLWATPZTKQT-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C10H11N5.ClH/c1-7-12-14-10(15-13-7)9-4-2-8(6-11)3-5-9;/h2-5H,6,11H2,1H3;1H
|
| Chemical Name |
[4-(6-methyl-1,2,4,5-tetrazin-3-yl)phenyl]methanamine;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (420.72 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (10.52 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (10.52 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.2072 mL | 21.0358 mL | 42.0716 mL | |
| 5 mM | 0.8414 mL | 4.2072 mL | 8.4143 mL | |
| 10 mM | 0.4207 mL | 2.1036 mL | 4.2072 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
